Lenvosiltamab: A Groundbreaking Advance in Multiple Myeloma Treatment
Learn about the remarkable response rate and complete response rate of Lenvosiltamab in multiple myeloma patients. Explore this potential paradigm shift in treatment.
Learn about the remarkable response rate and complete response rate of Lenvosiltamab in multiple myeloma patients. Explore this potential paradigm shift in treatment.
Supportive care is often started late in an illness, but that may not be the best way
Is appendectomy associated with a reduced risk of a colorectal cancer subtype positive for the tumor-promoting Fusobacterium nucleatum bacteria? A recent study investigated.
Loss of induction of immunogenic cell death in response to T-DM1 leads to resistance that can be overcome by targeting TACC3, providing an attractive strategy…
Major Finding: Atypical memory (AtM) B cells reside within the tumor microenvironment and suppress antitumor immunity. Concept: A single-cell, B-cell atlas reveals a noncanonical pathway…
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas,…
Deric Park, MD, discusses a phase 1/2 study of IGV-001, a novel treatment for glioblastoma.
In a pair of Special Reports, Gökbuget and colleagues present updated European Leukemia Net (ELN) consensus reports on (1) the diagnosis, prognostic factor
Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
Diepstraten et al. demonstrate that p53 enforces apoptosis induced by BH3-mimetic drugs. To boost BH3-mimetic-induced apoptosis in TP53-mutant blood cancers, STING agonists were employed to induce…
The annual Champions for Change Gala is The Skin Cancer Foundation’s signature fundraising event. Funds raised from the Gala support the Foundation’s lifesaving educational campaigns,…